European Institute of Oncology

The European Institute of Oncology, IEO, is a comprehensive cancer centre located in Milan, Italy. The institute strives for excellence in the prevention, diagnosis and treatment of cancer by developing clinical and scientific research coupled with innovative organization and management, in a context that pays constant attention to the quality of the services offered to patients.

The European Institute of Oncology was established to implement an innovative model for health and advanced research in the international oncology field. Its Division and Unit Directors come from eight European countries. 

The research laboratories of the Institute (the Department of Experimental Oncology, located at IFOM‐IEO Campus) are consistently developing and applying genomic research to the field of oncology, providing a substantial contribution to the quick translation of the emerging scientific knowledge into new strategies for the prevention and treatment of tumours. The IFOM‐IEO Campus represents one of the largest centres for cancer research in Europe.


This solid expertise makes IEO an optimal managing partner for the study of psychological aspects related to cancer screening and prevention, and to health-related behaviours. The daily experience with patients’ psycho-oncological support makes this Unit an optimal resource to understand patient and family needs in self management in cancer disease and thus to help creating tools for patient empowerment.

The competences on the cognitive processes of decision-making allows interfacing with more technical partners in order to develop decision aids taking into account not only normative decision rules, but personal values as well.

Furthermore, IEO documented experience with ICT for cancer disease management makes this centre a valuable member of the project in investigating the impact of iManageCancer on patients’ and family psychological well-being and quality of life. In particular, IEO will conduct small-scale pilots with patients with lung, breast and prostate cancer.